25 June 2022 – Xalkori (Crizotinib)-related ocular toxicity and severe visual loss are difficult to detect in children. This comes out of a Dear Healthcare Professional Communication (DHPC) letter from the European Medicine Agency (EMA) following it’s June 2022 Pharmacovigilance Risk Assessment …

Xalkori: Ocular Toxicity and Severe Visual Loss in Children Read more »

June 13, 2019 – This is simply fascinating stuff. Researchers are testing neural networks that automatically combine portrait photos with genetic and phenotypic patient data in order to obtain definitive diagnosis of hereditary rare diseases, all with the help of artificial …

Where portrait photos meet genetics and AI Read more »

December 12, 2018 – The application of CRISPR/Cas9 based molecular technology in the field of gene editing (or genome editing) has recently had its exploded limelight exposure for a couple of reasons. The question arises if this exposure is earned or …

CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy: Prime time already? Read more »

February 17, 2018 – In a new study, published in JAMA Oncology online on February 15, 2018, a comparison of the performance of 6 prognostic signatures for estrogen receptor (ER) –positive breast cancer was performed in a secondary analysis of a randomized …

Breast Cancer: Performance of prognostic signatures Read more »

May 18, 2017 – Ivacaftor (Kalydeco) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are carriers one of the following mutations in the CFTR gene: …

Theragenomics: Ivacaftor (Kalydeco) in the CFTR mutation-based treatment of cystic fibrosis (CF) Read more »

January 28, 2017 – One could call it a scandal. The dire reality is that what is described here could be widespread practice in the business of clinical trials performed and outcomes reported by Pharma, namely that only half of …

Massaging of data and outcomes: Can we ever trust clinical trial outcomes reported by Pharma? Read more »

September 09.  2016 – The pre-clinical animal model and Phase 1b placebo-controlled study in prodromal and mild Alzheimer Disease (AD) patients (n=165), both demonstrate that aducanumab reduced amyloid-beta in the brain and the reduction was dose-dependent. Amyloid-beta plaque is associated …

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Read more »